VU0238441-DataSheet-生命科學(xué)試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?Agonists?ScreeningLibrariesVU0238441Cat.No.:HY-12158CASNo.:85511-68-8分?式:C??H?ClF?NO?分?量:339.7作?靶點(diǎn):mAChR作?通路:GPCR/GProtein;NeuronalSignaling儲(chǔ)存?式:Powder-20°C3yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實(shí)驗(yàn)DMSO:125mg/mL(367.97mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲(chǔ)備液1mM2.9438mL14.7189mL29.4377mL5mM0.5888mL2.9438mL5.8875mL10mM0.2944mL1.4719mL2.9438mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲(chǔ)備液，并請(qǐng)注意儲(chǔ)備液的保存?式和期限。BIOLOGICALACTIVITY?物活性VU0238441泛毒蕈堿型?酰膽堿受體(mAChR)陽(yáng)性變構(gòu)調(diào)節(jié)劑(PAM)，對(duì)M1，M2，M3，M5和M4的EC50分別為3.2μM，2.8μM，2.2μM，2.1μM和>10μM。IC50&TargetEC50:3.2μM(M1),2.8μM(M2),2.2μM(M3),2.1μM(M5)and>10μM(M4)[1]體外研究VU0238441isananalogueofVU0119498[2].REFERENCES[1].ThomasMBridges,etal.ChemicalleadoptimizationofapanG(q)mAChRM(1),M(3),M(5)positiveallostericmodulator(PAM)lead.1/2PartI:DevelopmentofthefirsthighlyselectiveM(5)PAM.BioorgMedChemLett.2010Jan15;20(2):558-62.[2].ThomasMBridges,etal.DiscoveryofthefirsthighlyM5-preferringmuscarinicacetylcholinereceptorligand,anM5positiveallostericmodulatorderivedfromaseriesof5-trifluoromethoxyN-benzylisatins.JMedChem.2009Jun11;52(11):3445-8.McePdfHeightMedChemExpress(MCE)只為有資質(zhì)的科研機(jī)構(gòu)、醫(yī)藥企業(yè)基于科學(xué)研究或藥證申報(bào)的?途提供醫(yī)藥研發(fā)服務(wù)，

不為任何個(gè)?或者?科研性質(zhì)的、??于藥證申報(bào)使?等